Consistency of Clopidogrel Prescribing to Its indications for Patients with Coronary Heart Disease in Rangae Hospital, Narathiwat
Article Sidebar
Main Article Content
Abstract
Objective: To determine the percentage of clopidogrel prescribing consistent with its indications for coronary heart disease patients in Ranga hospital, Narathiwat, and to determine association between the length of time patients receiving aspirin and clopidogrel with the occurrence of adverse drug reactions to the gastrointestinal tract in those with concomitant use of the drugs for a period of up to 1 year and those with more than one year. Methods: This was a retrospective cross-sectional study that collected data in coronary heart disease patients with clopidogrel prescribing from the electronic medical record database in the HOSxP program from October 1, 2018 to September 30, 2019. Results: 81.40% of the prescription for clopidogrel in patients with coronary heart disease was consistent with its indications. The length of time patients receiving aspirin plus clopidogrel was significantly associated with adverse drug reactions to the gastrointestinal tract (P=0.017). Conclusion: Clopidogrel prescribing consistent to its indications would reduce the unnecessary cost of drug in the hospital. The hospital should monitor gastrointestinal complications, especially in patients receiving the drug for more than 1 year, but other factors affecting drug use should also be considered. Multidisciplinary participation is needed in the development of guidelines for providing services to patients with coronary heart disease using clopidogrel.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
World Health Organization. The top 10 causes of death [online]. 2018[cited May 1, 2020]. Available from: www.who.int/news-room/fact-sheets/detail/th e-top-10-causes-of-death.
Strategy and Planning Division, Ministry of Public Health. Public health statistics A.D. 2017[online]. 2018 [cited Dec10, 2019]. Available from: bps.moph.go.th/new_bps/sites/default/files/statistics60.pdf
Kositchaiwat J. Thai acute coronary syndromes guide lines 2020. Bangkok: Heart Association of Thailand; 2020. p.15-42.
Heart Association of Thailand. Percutaneous coro nary intervention, PCI guideline [online]. 2017 [cited May 1, 2020]. Available from: www.thaiheart.org.
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol 2016; 68: 1082-115.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39: 213-54.
Public Health Administration. Guidelines for drug management in the service plan: cardiology and nephrology. Nonthaburi: Ministry of Public Health; 2020. p.18.
Yin SH, Xu P,Wang B, Lu Y, Wu QY, Zhou ML, et al. Duration of dual antiplatelet therapy after percuta neous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019; 365, l2222. doi: 10.1136/bmj.l2222.
National Drug Committee. Thailand national list of essential medicines 2018. Nonthaburi: Food and Drug Administration Thailand; 2018.
Elmariah S, Doros G, Bhatt DL, Yusuf S, Steinhubl SR, Liu Y, et al. Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease. Circ Cardiovasc Interv. 2018; 11: e005795. doi:10.1161/CIRCINTER VENTIONS.117.005795.:e005795.
Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Long- term out comes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008; 102: 1618-23.
Sorensen R OJ, Charlot M, Gislason GH. Risk of bleeding related to antithrombotic treatment in cardiovascular disease. Curr Pharm Des. 2012; 18: 5362-78.
FDA Drug Safety Communication. FDA Reviews long-term antiplatelet therapy as preliminary trial data show benefits but a higher risk of non-cardiovascular death [online]. 2014 [cited May 1, 2020]. Available from: www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communicati on-fda-review-finds-long-term-treatment-blood-thin ning-medicine-plavix
National Health Security Office Region 12 Songkhla. The 2018 performance Report. Songkhla: National Health Security Office Region 12 Songkhla; 2018.
Krejcie RV, Morgan DW. Determining sample size for research activities. Educ Psy Measure 1970; 30: 607-10.
Kongsin N, Sappawittayakul K. Rational drug use of clopidogrel. The Southern College Network Journal of Nursing and Pubic Health 2014; 1: 17-24.
Ploylearmsang C, Teinkanitikul K, Choppradit C, Soonthorn S, Patisonthi K. Development of compu- terized decision support program on prescribing high risk CNS drugs for aging outpatients in hospitals. Academic Psychiatry and Psychology Journal 2020; 36: 200-21.
Klaypaksi A, Polnok A. Effect of computerized clinical decision support system on medication use in patients with renal impairment. Thai Journal of Pharmacy Practice 2020; 12: 437-51.
Chatrattanakulchai B. Incidence and related factors of upper gastrointestinal bleeding and development of pharmaceutical care practice guidelines for patients with aspirin and clopidogrel. [dissertation]. Nakhornpathom: Silpakorn University; 2017.
Saneha S, Areepium N. Incidence of gastrointestinal bleeding in Thai patients with acute coronary syndrome in concomitant use of dual antiplatelet therapy and proton pump inhibitors. Thai Journal of Pharmacy Practice 2021; 13: 242-50.
